Concepedia

Author

Luisa Shin Ogawa

Synta Pharmaceuticals (United States)

Also Known As

L S Ogawa, L. Shin Ogawa, L.S. Ogawa, Luisa S. Ogawa, Luisa Shin Ogawa

78

Publications

874

Citations

10

H-Index

47

Concepts

All Affiliations

Synta Pharmaceuticals (United States)Cairn UniversityVA Boston Healthcare SystemFox Chase Cancer Center
LS

About

Luisa Shin Ogawa is an author at Synta Pharmaceuticals (United States) specializing in medicine, pharmacology, and cancer research.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

5

5

596

2

Health Sciences

1

1

10

3

Allergy

1

1

19

4

Biochemistry

1

1

330

5

Cell Biology

1

1

10

Luisa Shin Ogawa

×

11

Publications

860

Citations

10

H-Index

YearCitations

The oncology drug elesclomol selectively transports copper to the mitochondria to induce oxidative stress in cancer cells

Masazumi Nagai, Nha Huu Vo, Luisa Shin Ogawa,

Free Radical Biology and Medicine

2012

330

Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy

Weiwen Ying, Zhenjian Du, Lijun Sun,

Molecular Cancer Therapeutics

2011

227

FGFR3 Translocations in Bladder Cancer: Differential Sensitivity to HSP90 Inhibition Based on Drug Metabolism

Jaime Acquaviva, Suqin He, Chaohua Zhang,

Molecular Cancer Research

2014

75

A rat retinal damage model predicts for potential clinical visual disturbances induced by Hsp90 inhibitors

Dan Zhou, Yuan Liu, Josephine Ye,

Toxicology and Applied Pharmacology

2013

71

UDP glucuronosyltransferase 1A expression levels determine the response of colorectal cancer cells to the heat shock protein 90 inhibitor ganetespib

Hannes Landmann, David A. Proia, Sen He,

Cell Death and Disease

2014

41

HSP90 Inhibitor–SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors

David A. Proia, Donald L. Smith, Junyi Zhang,

Molecular Cancer Therapeutics

2015

33

A Novel HSP90 Inhibitor–Drug Conjugate to SN38 Is Highly Effective in Small Cell Lung Cancer

Anna V. Gaponova, Anna S. Nikonova, Alexander Y. Deneka,

Clinical Cancer Research

2016

32

The HSP90 Inhibitor Ganetespib Alleviates Disease Progression and Augments Intermittent Cyclophosphamide Therapy in the MRL/lpr Mouse Model of Systemic Lupus Erythematosus

Yuan Liu, Josephine Ye, Luisa Shin Ogawa,

PLoS ONE

2015

19

Consecutive Day HSP90 Inhibitor Administration Improves Efficacy in Murine Models of KIT-Driven Malignancies and Canine Mast Cell Tumors

Cheryl A. London, Jaime Acquaviva, Donald L. Smith,

Clinical Cancer Research

2018

12

Abstract C212: A critical role for the tissue distribution profile in heat shock protein (Hsp) 90 inhibitor-induced ocular toxicity in rats.

Dan Zhou, Yuan Liu, Josephine Ye,

Molecular Cancer Therapeutics

2011

10

Page 1